Thank you very much. Good morning, and thank you for joining our third quarter earnings call. I'm going to jump straight into it today and maybe look at some of the highlights from the third quarter. We continue to exhibit double-digit organic growth and margin expansion in the quarter. We had strong adjusted EBITDA growth, and we improved our cash flow from our operations. And we passed an important milestone when we entered into an adjacent and additional MedTech niche by acquiring a business in the veterinary dentistry space. I want to go through a little bit more in detail on what was driving these results. So first of all, 10% organic revenue growth. And it's driven by our Specialty Pharma and our MedTech and Veterinary Services segments, which both showed very strong growth. And our adjusted EBITDA grew by 20% and ended up being 21.9 million. Our EBITDA margin came in at 25% year-over-year, and that’s also an improvement. If we turn to our Specialty Pharma segment, we see strong growth here with 13%. We experienced very strong growth across all of our therapeutic areas. As you know, we've discussed our growth initiative. The one focus point to drive organic growth is our cross-selling initiative. And that initiative alone yielded one third of the growth. The positive margin development seen in Specialty Pharma is driven by a continued focus on integrating our acquisitions and optimizing the business overall. And the adjusted EBITDA grew by 24% in this part of our business. If we then turn to MedTech, the organic growth in this segment was 4%. And it's driven by factors that make it slower than in Q2. It's driven by softness in the U.S. high-cost surgical elective market, specifically in areas like knees and hips. And today, we don't see any sign of recovery in this part of the segment.
In our European and APAC businesses, we had continued high single-digit growth. The margin improvement here is driven by the annual order program, where we have now flattened out our sales of those products across each quarter, which has evened out our margin profile over the quarters and the years as well. Um, our initiative to drive growth in MedTech is all about capturing the white space. We do that mostly by way of education and conducted over 20 on-site educations with almost 300 participants in the third quarter; our adjusted EBITDA for MedTech grew by 19%. We then switch over to our veterinary services business. Um, very strong growth here of 17%, and we see positive momentum across all of our key geographies in the business. Our initiative for growth in veterinary services, as you know, is all centered around acquiring new members, and we added 250 new clinics to our membership, for a total of 8,200. At the end of the quarter, margins were up substantially here. And it's really because of our higher penetration of services among existing customers. And we're seeing good benefits from the scale that this business is now starting to drive. And the EBITDA growth for veterinary services came in at 34%, which is an exceptional growth rate for this business.
Now turning to our fourth and last segment.
Diagnostics business accounts for about 5% of our total business, and we continue to see a decline in this segment by 5%. The end markets here, which focus on livestock, have unchanged characteristics. The profitability in this business is lower because we have launched a parasitology test for the companion animal sector, where we are refocusing and diversifying this segment of our business into companion animals. And we'll continue that effort in the future as well. And with that said, maybe we can switch over to discussing the acquisition we just completed. We're very excited about having completed the iM3 acquisition. Um, it's a global leader in the veterinary dental space. Just as a reminder of our strategy, we've said that the M&A strategy involves adding products or geographies into our existing platforms in Specialty Pharma, MedTech, or Veterinary Services. We also said that we're looking for new therapeutic areas for Specialty Pharma and MedTech. And this is precisely a new therapy area for our MedTech business. We're excited to have acquired the global leader in the veterinary dental space. iM3 has very strong brand recognition in this niche. The niche grows very fast and has very high customer satisfaction. And as we've said before. But just as a reminder, this acquisition would add about $7.7 million in EBITDA, and we consolidated the business into our operations here on October 1st this year.
We wanted to look a little bit closer at the company. It's a family-owned business that was founded in Australia about 30 years ago. That has been a very, very successful endeavor. Um, customers in over 40 countries selling both directly and through distribution. We're adding 85 employees to the family and welcome them to our company. And we have offices in the US, Australia, Ireland, and the UK. And just like we have in our orthopedics business, whitespace capture and education are key drivers for growth here. iM3 has a number of state-of-the-art education centers that can be used for both dental and orthopedic education. So, we're very excited to add more capabilities here.
If we look at additional acquisitions in this segment, we are looking at driving acquisitions that will help us improve and increase the margin profile of the business. That includes consumables businesses and distribution businesses that will help us achieve that. If we look at our product portfolio in here, we have some very specialized dental units, X-ray units, instruments that are used for the actual surgical or dental procedures, some small equipment, services, and consumables. So today, about 32% of the revenue from this business is of a recurring nature. So with that said, I'm going to end my piece here and hand over to Carl-Johan to walk us through a little bit more details on the financials.
Over to you. Carl. Carl-Johan.